MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

ET to provide a corporate update and review the Company’s results for the year ended December 31, 2023.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, February 22, 2024
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Webcast, Medicine, MindMed
Geotags: 
NEW YORK, NORTH AMERICA, UNITED STATES, UNITED KINGDOM, EUROPE, CANADA, CHICAGO
Stock Symbol: 
NASDAQ:MNMD
NEO:MMED
Summary
Key Points: 
  • ET to provide a corporate update and review the Company’s results for the year ended December 31, 2023.
  • Listeners can register for the webcast via this link .
  • A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/ , and archived for at least 30 days after the webcast.
  • Those who plan on participating are advised to join 15 minutes prior to the start time.


Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, February 28, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company’s results for the year ended December 31, 2023.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine, and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Cboe Canada exchange (formerly the NEO Exchange) under the symbol MMED.

Copyright: 
Copyright Business Wire 2024